Impact of anti-angiogenic treatments on metastatic renal cell carcinoma

References

• Scelo G, Brennan P. The epidemiology of bladder and kidney cancer. Nat. Clin. Pract. Urol.4, 205–217 (2007).
   PubMedGoogle Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med.335, 865–875 (1996).
   PubMed Web of Science ®Google Scholar
• Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J. Clin. Oncol.12, 206–212 (1994).
   PubMed Web of Science ®Google Scholar
• Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. North Am.30, 843–852 (2003).
   PubMed Web of Science ®Google Scholar
• van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer5, 57 (2005).
   PubMed Web of Science ®Google Scholar
• Na X, Wu G, Ryan CK, Schoen SR, di’Santagnese PA, Messing EM. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 α expression in renal cell carcinomas. J. Urol.170, 588–592 (2003).
   PubMed Web of Science ®Google Scholar
• McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol.23, 133–141 (2005).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Murphy BA, Bacik J et al. Phase III trial of interferon α-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J. Clin. Oncol.18, 2972–2980 (2000).
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N. Engl. J. Med.338, 1272–1278 (1998).
   PubMed Web of Science ®Google Scholar
• Fossa SD. Interferon in metastatic renal cell carcinoma. Semin. Oncol.27, 187–193 (2000).
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X et al.In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res.9, 327–337 (2003).
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol.24, 25–35 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA295, 2516–2524 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Rosenberg J et al. Sunitinib efficacy against advanced renal cell carcinoma. J. Urol.178, 1883–1887 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon α in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27, 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol.26, 3743–3748 (2008).
   PubMed Web of Science ®Google Scholar
• Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol.10, 757–763 (2009).
   PubMed Web of Science ®Google Scholar
• Escudier B, Roigas J, Gillessen S et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J. Clin. Oncol. (2009).
   Google Scholar
• Sunitinib (Sutent®) package insert. Pfizer Inc, NY, USA (2007).
   Google Scholar
• Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist13, 1084–1096 (2008).
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can. Urol. Assoc. J.1, S41–54 (2007).
   Web of Science ®Google Scholar
• Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet370, 2011–2019 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst.99, 81–83 (2007).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr. Pharm. Des.8, 2255–2257 (2002).
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 2505–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356, 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol.27, 3312–3318 (2009).
   PubMed Web of Science ®Google Scholar
• Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol.182, 29–34 (2009).
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Hutson TE et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon α-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27, 1280–1289 (2009).
   PubMed Web of Science ®Google Scholar
• Beck J, Verzoni E, Negrier S et al. A large open-label, non-comparative Phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur. J. Cancer7(Suppl.), 244 (2007) (Abstract 4506).
   Google Scholar
• Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol.9, 117–123 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK et al. Pharmacokinetic–pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther.6, 2012–2021 (2007).
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Hutson TE, Sternberg CN. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin. Investig. Drugs17, 253–261 (2008).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Szczylik C, Lee E. A randomized, double-blind Phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol.27, 15s (2009).
   Google Scholar
• Rugo HS, Herbst RS, Liu G et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol.23, 5474–5483 (2005).
   PubMed Web of Science ®Google Scholar
• Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a Phase II study. Lancet Oncol.8, 975–984 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Wilding G, Hudes G et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol.27(27), 4462–4468 (2009).
   PubMed Web of Science ®Google Scholar
• Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin. Cancer Res.13, 3109–3114 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas GV, Tran C, Mellinghoff IK et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med.12, 122–127 (2006).
   PubMed Web of Science ®Google Scholar
• Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol.22, 2336–2347 (2004).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol.22, 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356, 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann. Oncol.19, 1387–1392 (2008).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372, 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hudes G, Wilding G et al. Phase I trial of sunitinib malate plus interferon-α for patients with metastatic renal cell carcinoma. Clin. Genitourin. Cancer7, 28–33 (2009).
   PubMed Web of Science ®Google Scholar
• Gollob JA, Rathmell WK, Richmond TM et al. Phase II trial of sorafenib plus interferon α-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J. Clin. Oncol.25, 3288–3295 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol.24, 5601–5608 (2006).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370, 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon α compared with interferon α monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol.26, 5422–5428 (2008).
   PubMed Web of Science ®Google Scholar
• Eisen T, Oudard S, Szczylik C et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J. Natl Cancer Inst.100, 1454–1463 (2008).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol.20, 2376–2381 (2002).
   PubMed Web of Science ®Google Scholar
• Lin ZH, Han EM, Lee ES et al. A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas. Mod. Pathol.17, 611–616 (2004).
   Google Scholar
• Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene22, 847–852 (2003).
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol.26, 127–131 (2008).
   PubMed Web of Science ®Google Scholar
• Dutcher JP, de Souza P, McDermott D et al. Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med. Oncol.26, 202–209 (2009).
   PubMed Web of Science ®Google Scholar
• Henderson C, Bukowski RM, Stadler WM et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Subset analysis of patients (pts) with brain metastases (BM). J. Clin. Oncol.ASCO Annual Meeting Proceedings Part I.25, (2007) (abstract 15506).
   Google Scholar
• Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17, 2530–2540 (1999).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bukowski RM, Figlin RA et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer113, 1552–1558 (2008).
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon a alone in metastatic renal-cell carcinoma: a randomised trial. Lancet358, 966–970 (2001).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Yonover PM. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin. Urol. Oncol.19, 98–102 (2001).
   PubMedGoogle Scholar
• Biswas S, Kelly J, Eisen T. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist14, 52–59 (2009).
   Google Scholar
• Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res.9, 802–811 (2003).
   PubMed Web of Science ®Google Scholar
• Sorafenib (Nexavar®) package insert. Bayer Pharmaceuticals Corp, Leverkusen, Germany (2006).
   Google Scholar
• Temsirolimus (Torisel®) package insert. Wyeth Pharmaceuticals, Inc, PA, USA (2007).
   Google Scholar
• Everolimus (Afinitor®) package insert. Norvartis Pharmaceutical Corporation, NJ, USA (2009).
   Google Scholar